Inovio Pharmaceuticals
Inovio Pharmaceuticals is a clinical-stage biotechnology company focused on developing DNA medicines to fight HPV-related diseases, cancer, and infectious diseases. They leverage proprietary technology to design DNA plasmids and use investigational CELLECTRA® devices for delivery, aiming to teach the body to produce disease-fighting proteins. Their platform offers advantages such as tolerability, versatility, immunogenicity, and scalability, with ongoing research in next-generation DNA medicines including DNA-encoded monoclonal antibodies, DNA-launched nanoparticles, and innovative delivery techniques. The company's mission is to develop innovative therapies to improve lives worldwide.
Industries
Nr. of Employees
large (251-1000)
Inovio Pharmaceuticals
Plymouth Meeting, Pennsylvania, United States, North America
Products
VGX-3100 (therapeutic DNA vaccine candidate)
Therapeutic synthetic DNA vaccine candidate evaluated for treatment of HPV-associated cervical dysplasia and related indications.
INO-3107 (DNA immunotherapy candidate for recurrent respiratory papillomatosis)
DNA immunotherapy candidate evaluated in Phase 1/2 studies for HPV-6/11-associated recurrent respiratory papillomatosis.
INO-4800 (SARS-CoV-2 DNA vaccine candidate)
DNA vaccine candidate against SARS-CoV-2 evaluated in preclinical and early clinical studies for immunogenicity and durability of response.
DNA-encoded monoclonal antibody candidates (DMAb platform)
Platform approach and specific DMAb candidates delivering DNA sequences encoding monoclonal antibodies to enable in vivo antibody production for infectious disease and oncology applications.
Electroporation delivery devices (investigational delivery platform)
Investigational electroporation delivery systems designed to transiently permeabilize cell membranes after intradermal or intramuscular injection of DNA plasmids to enhance cellular uptake.
VGX-3100 (therapeutic DNA vaccine candidate)
Therapeutic synthetic DNA vaccine candidate evaluated for treatment of HPV-associated cervical dysplasia and related indications.
INO-3107 (DNA immunotherapy candidate for recurrent respiratory papillomatosis)
DNA immunotherapy candidate evaluated in Phase 1/2 studies for HPV-6/11-associated recurrent respiratory papillomatosis.
INO-4800 (SARS-CoV-2 DNA vaccine candidate)
DNA vaccine candidate against SARS-CoV-2 evaluated in preclinical and early clinical studies for immunogenicity and durability of response.
DNA-encoded monoclonal antibody candidates (DMAb platform)
Platform approach and specific DMAb candidates delivering DNA sequences encoding monoclonal antibodies to enable in vivo antibody production for infectious disease and oncology applications.
Electroporation delivery devices (investigational delivery platform)
Investigational electroporation delivery systems designed to transiently permeabilize cell membranes after intradermal or intramuscular injection of DNA plasmids to enhance cellular uptake.
Services
Clinical trial participation and investigational therapy access
Enrollment and conduct of investigator-led and company-sponsored early-phase clinical trials for DNA medicine candidates; patient and investigator contact information provided for trial inquiries.
Clinical trial participation and investigational therapy access
Enrollment and conduct of investigator-led and company-sponsored early-phase clinical trials for DNA medicine candidates; patient and investigator contact information provided for trial inquiries.
Expertise Areas
- DNA medicine development
- Delivery device engineering and manufacturing
- Electroporation-based nucleic acid delivery
- DNA-encoded monoclonal antibody development
Key Technologies
- Synthetic DNA plasmid design
- Computational plasmid optimization algorithms
- Electroporation delivery systems
- Vacuum-assisted intradermal delivery